Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Koninklijke Philips NV — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.14, while Koninklijke Philips NV trades at $26.84 (market cap $26.58B). The key difference: Koninklijke Philips NV pays a 3.75% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none, and Koninklijke Philips NV is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| LQD | PHG | |
|---|---|---|
52-Week High | $112.91 | $32.91 |
52-Week Low | $105.96 | $25.02 |
Market Cap | — | $26.58B |
Sector | — | Health |
Enterprise Value | — | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $106.215, up 0.24% with bearish technical signals from moving averages. The ETF shows neutral oscillator readings while facing pressure from rising Treasury yields and inflation concerns. Recent dividend distributions provide income support, but technical indicators suggest caution with 17 sell signals versus 2 buy signals.
The outlook remains challenged by bond market volatility and Fed policy uncertainty. Investment opportunities exist for income-focused investors through dividends, but risks include interest rate sensitivity and macroeconomic pressures from oil price fluctuations and geopolitical tensions affecting fixed income markets.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
